Attached files
| file | filename |
|---|---|
| EX-10.6 - EX-10.6 - Intra-Cellular Therapies, Inc. | d101832dex106.htm |
| EX-31.2 - EX-31.2 - Intra-Cellular Therapies, Inc. | d101832dex312.htm |
| EX-14.1 - EX-14.1 - Intra-Cellular Therapies, Inc. | d101832dex141.htm |
| EX-31.1 - EX-31.1 - Intra-Cellular Therapies, Inc. | d101832dex311.htm |
| EX-10.7 - EX-10.7 - Intra-Cellular Therapies, Inc. | d101832dex107.htm |
| EX-10.11 - EX-10.11 - Intra-Cellular Therapies, Inc. | d101832dex1011.htm |
| 10-K - FORM 10-K - Intra-Cellular Therapies, Inc. | d101832d10k.htm |
| EX-32.1 - EX-32.1 - Intra-Cellular Therapies, Inc. | d101832dex321.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-8 No. 333-205070) pertaining to the Intra-Cellular Therapies, Inc. Amended and Restated 2013 Equity Incentive Plan of Intra-Cellular Therapies, Inc.,
(2) Registration Statement (Form S-3 No. 333-204509) of Intra-Cellular Therapies, Inc.,
(3) Registration Statement (Post-Effective Amendment No. 3 to Form S-1 on Form S-3 No. 333-191238) of Intra-Cellular Therapies, Inc., and
(4) Registration Statement (Form S-8 No. 333-193310) pertaining to the ITI, Inc. 2003 Equity Incentive Plan, as amended, and the Intra-Cellular Therapies, Inc. 2013 Equity Incentive Plan of Intra-Cellular Therapies, Inc.;
of our reports dated February 25, 2016, with respect to the consolidated financial statements of Intra-Cellular Therapies, Inc. and the effectiveness of internal control over financial reporting of Intra-Cellular Therapies, Inc. included in this Annual Report (Form 10-K) of Intra-Cellular Therapies, Inc. for the year ended December 31, 2015.
/s/ Ernst & Young LLP
Baltimore, MD
February 25, 2016